MedPath

Evaluation of Colorectal Cancer Screening Strategies in China

Not Applicable
Conditions
Colorectal Neoplasms
Interventions
Diagnostic Test: Qualitative Fecal immunochemical test + APCS score
Diagnostic Test: Quantitative Fecal immunochemical test
Registration Number
NCT05440552
Lead Sponsor
Shandong University
Brief Summary

A large-scale randomized controlled trial was conducted to compare different colorectal neoplasms screening strategies in China.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
20000
Inclusion Criteria
  • 50-74 years old
  • Informed consent is available
Exclusion Criteria
  • Previous colorectal cancer
  • Previous colorectal resection
  • Previous received cancer-related treatment (except non-melanoma skin cancer)
  • Colonoscopy, sigmoidoscopy, CT colonoscopy, and barium enema were performed within 5 years
  • Fecal occult blood or fecal DNA was performed within one year
  • Symptoms of lower digestive tract diseases requiring colonoscopy include: (1) rectal bleeding occurred more than once in the past 6 months, (2) recorded iron deficiency anemia, and (3) recorded significant weight loss within 6 months (> 10% of baseline weight - Suffering from other diseases that affect the benefit of screening or intolerance to colonoscopy (for example, severe pulmonary disease, end-stage renal disease, end-stage liver disease, severe heart failure or recently diagnosed cancer, except non-melanoma skin cancer)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Risk score1Qualitative Fecal immunochemical test + APCS score-
Risk score2Quantitative Fecal immunochemical test-
Primary Outcome Measures
NameTimeMethod
Detection rateup to 30 months

Detection of intestinal lesions

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath